| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11944594 | AGEPHA PHARMA FZ | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
Nov, 2033
(9 years from now) | |
| US11944595 | AGEPHA PHARMA FZ | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
Nov, 2033
(9 years from now) | |
| US10130585 | AGEPHA PHARMA FZ | Methods of treating and/or preventing cardiovascular disease |
Dec, 2034
(10 years from now) | |
| US11026900 | AGEPHA PHARMA FZ | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
Jan, 2035
(10 years from now) | |
| US11026899 | AGEPHA PHARMA FZ | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
Jan, 2035
(10 years from now) | |
| US10842762 | AGEPHA PHARMA FZ | Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent |
Jan, 2035
(10 years from now) | |
| US10265281 | AGEPHA PHARMA FZ | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
Jan, 2035
(10 years from now) | |
| US10206891 | AGEPHA PHARMA FZ | Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent |
Jan, 2035
(10 years from now) | |
| US9744144 | AGEPHA PHARMA FZ | Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent |
Jan, 2035
(10 years from now) | |
| US11026901 | AGEPHA PHARMA FZ | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
Jan, 2035
(10 years from now) | |
Lodoco is owned by Agepha Pharma Fz.
Lodoco contains Colchicine.
Lodoco has a total of 10 drug patents out of which 0 drug patents have expired.
Lodoco was authorised for market use on 16 June, 2023.
Lodoco is available in tablet;oral dosage forms.
Lodoco can be used as a method of treating and/or reducing the risk of inflammation, atherosclerotic vascular disease, and cholesterol crystal induced inflammation within atherosclerotic plaques, a method for treating and/or reducing the risk of acute myocardial infarction, method for reducing a risk of at least one cardiovascular event, a method for treating and/or reducing the risk of a cardiovascular event, a method of treating cardiovascular disease, a method of treating and/or reducing the risk of a cardiovascular event; acute coronary syndrome, out-of-hospital cardiac arrest, and/or noncardioembolic ischemic stroke, method for reducing acute myocardial infarction risk, method of treating and/or reducing the risk of a cardiovascular event.
The generics of Lodoco are possible to be released after 22 January, 2035.
Drugs and Companies using COLCHICINE ingredient
Market Authorisation Date: 16 June, 2023
Treatment: Method for reducing a risk of at least one cardiovascular event; Method for reducing acute myocardial infarction risk; A method of treating cardiovascular disease; A method for treating and/or reducin...
Dosage: TABLET;ORAL
LODOCO family patents
